SETD8 inhibits apoptosis and ferroptosis of Ewing’s sarcoma through YBX1/RAC3 axis

• Published in: Cell death & disease 2024-07, Vol.15 (7), p.494-14, Article 494
• Main Authors: Chen, Huimou, Hu, Jing, Xiong, Xilin, Chen, Hongling, Liao, Qiaofang, Lin, Biaojun, Chen, Yusong, Peng, Yanting, Li, Yang, Cheng, Di, Li, Zhihua
• Format: Article
• Language: English
• Subjects: 13/109; 631/67/1059/602; 631/67/2332; 82/1; 96/2; 96/31; 96/98; Animal models; Animals; Antibodies; Apoptosis; Biochemistry; Biomedical and Life Sciences; Cell Biology; Cell Culture; Cell death; Cell Line, Tumor; Female; Ferroptosis; Ferroptosis - genetics; Gene Expression Regulation, Neoplastic; Histone H4; Histone methyltransferase; Histone-Lysine N-Methyltransferase - genetics; Histone-Lysine N-Methyltransferase - metabolism; Humans; Immunology; Life Sciences; Lysine; Mass spectroscopy; Medical innovations; Methylation; Mice; Mice, Nude; Nuclear transport; Patients; Pediatrics; Post-transcription; Proteomics; RNA-mediated interference; Sarcoma; Sarcoma, Ewing - genetics; Sarcoma, Ewing - metabolism; Sarcoma, Ewing - pathology; Therapeutic targets; Tumorigenesis; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-024-06882-5

Ewing’s sarcoma (ES) represents a rare yet exceedingly aggressive neoplasm that poses a significant health risk to the pediatric and adolescent population. The clinical outcomes for individuals with relapsed or refractory ES are notably adverse, primarily attributed to the constrained therapeutic alternatives available. Despite significant advancements in the field, molecular pathology-driven therapeutic strategies have yet to achieve a definitive reduction in the mortality rates associated with ES. Consequently, there exists an imperative need to discover innovative therapeutic targets to effectively combat ES. To reveal the mechanism of the SETD8 (also known as lysine methyltransferase 5A) inhibitor UNC0379, cell death manners were analyzed with different inhibitors. The contributions of SETD8 to the processes of apoptosis and ferroptosis in ES cells were evaluated employing the histone methyltransferase inhibitor UNC0379 in conjunction with RNA interference techniques. The molecular regulatory mechanisms of SETD8 in ES were examined through the application of RNA sequencing (RNA-seq) and mass spectrometry-based proteomic analysis. Moreover, nude mouse xenograft models were established to explore the role of SETD8 in ES in vivo. SETD8, a sole nucleosome-specific methyltransferase that catalyzes mono-methylation of histone H4 at lysine 20 (H4K20me1), was found to be upregulated in ES, and its overexpression was associated with dismal outcomes of patients. SETD8 knockdown dramatically induced the apoptosis and ferroptosis of ES cells in vitro and suppressed tumorigenesis in vivo. Mechanistic investigations revealed that SETD8 facilitated the nuclear translocation of YBX1 through post-transcriptional regulatory mechanisms, which subsequently culminated in the transcriptional upregulation of RAC3 . In summary, SETD8 inhibits the apoptosis and ferroptosis of ES cells through the YBX1/RAC3 axis, which provides new insights into the mechanism of tumorigenesis of ES. SETD8 may be a potential target for clinical intervention in ES patients.